Spring direct naar de hoofdnavigatie of de inhoud
‘In the end it's all about the value that the patent adds to the product.’
Mark Einerhand

Mark Einerhand

  • Life Sciences
  • European and Dutch Patent Attorney
  • Partner

Mark Einerhand has been active in the patent world since 1998, when he made the switch from a biotech startup to V.O.

Mark’s career started in science. After his studies of molecular biology at the University of Amsterdam, he took his PhD in medical science inLeiden, in 1992. He was a visiting scientist at Cornell University in New York and the MRC at Mill Hill in London.

Continue reading

His particular expertise lies in the field of medical (bio)technology, diagnostics and medicines. Because of his background at Introgene/Crucell, Mark has a special affinity with Life Science startups. He has a wide experience in patent cases before the court in The Hague.

Working experience

  • Patent Attorney, V.O. (1998-present)
  • IntroGene (now Crucell), Rijswijk (1995)
  • Post-Doc at Leiden University (1993)
  • Medical Research Council, Mill Hill, London (1992)
  • Visiting Scientist, Cornell University New York (1992)

Education

  • PhD in Medicine, Leiden University (1992)
  • MSc in Biochemistry, University of Amsterdam (1987), Major in Molecular Oncology, Dutch Cancer Institute

Publications

  • Co-author of article ‘The patentability of stem cells in Europe’, IAM Life Sciences 2015.
    Einerhand, M.P.W. (2011): Advance offering of generics found to infringe. Managing Intellectual Property: Vol 205: page: 87.
  • Einerhand M.P.W. (2010): A contribution to: Legal and intellectual property issues associated with stem cells. In: Stem Cells; scientific facts and fiction, (C. Mummery; I. Wilnut, A van de Stolpe and
    B.A.J. Roelen), Academic Press: Elsevier.
  • Einerhand M.P.W. and van Melle, J (2004): Patenting of inventions in the field of bio-informatics.
    In: The new avenues in Bioinformatics, (Seckbach, J and Rubin, E eds), Kluwer Academic Publishers, the Netherlands.
  • Principle inventor on Patents and Patent Applications: Einerhand, M.P.W. and Valerio (1997). WO 98/32870: US 6,232,105: A conditional replication and expression system. Einerhand, M.P.W. and Valerio (1997). WO 99/32647: Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into chromosomal DNA of target cells in gene therapy. Einerhand, M.P.W. and Valerio (1996). WO98/24924: NZ 336185:
  • Transduction of primate hemopoietic repopulating stem cells. Einerhand, M.P.W. and Valerio (1995). WO 97/20943: US 6,140,103: Regulated protein expression in stably transfected mammalian cells. Einerhand, M.P.W. (1992) Gene transfer into hemopoietic stem cells: prospects for human gene therapy. University of Leiden.

Professional & Community Activities

  • Member of the Steering Committee World IP Forum 2015
    Former member of the European Qualifying Examination committee III

Languages

  • English
  • Dutch
  • German

Also see these experts

Hajo Kraak

Hajo Kraak

  • European and Dutch Patent Attorney, European Patent Litigator
  • Partner
Marijke Westra

Marijke Westra

  • European and Dutch Patent Attorney, European Patent Litigator
  • Senior Associate
More experts

News

Netherlands Patent Attorney Firm of the Year

Since October 17, V.O. can proudly call itself “Netherlands Patent Attorney Firm of the Year. On behalf of our firm, Sjoerd Postma and Marijke Westra received this honorable award from IAM and WTR in London, where all winners of the 2024 Global IP Award were announced.Continue reading

Research exemptions under Belgian patent law before and after 1 June 2023

A research exemption is a provision in patent law that allows researchers to perform Research and Development (R&D) on patented inventions without infringing on the patent holder’s rights. In Belgium, the research exemption was one of the broadest in Europe until 31 May 2023.Continue reading

Recognitions by IP STARS andWho’s Who Legal

We are again proud of our recent recognitions by IP STARS (Managing IP) as a Tier 1 firm and for Belgium as a Tier 2 firm. And a Tier 3 listing for Trademark Prosecution. Individual recommendations as ‘IP Stars 2024’ are for Tamara Elmore, Bettina Hermann, Annemie Jaeken, Leo Jessen, Bernard Ledeboer, Marco Molling, Otto […]Continue reading